Page 20 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology Progress in the research of pathology and therapy in liver fibrosis

a potent technology to increase systemic circulation and Availability of data
localization of anti-fibrosis drugs within the fibrotic liver.
The permeability and retention effect of these drugs can be Not applicable.
enhanced by conjugating them with collagenase I-decorated References
NPs. Achieving hepatic fibrogenesis inhibition through
multiple pathways within a single treatment period may 1. Yang LX, Qi C, Lu S, et al. Alleviation of liver fibrosis by
only be feasible with an advanced targeted delivery system. inhibiting a non-canonical ATF4-regulated enhancer program
in hepatic stellate cells. Nat Commun. 2025;16(1):524.
In recent years, TCM has made great progress in doi: 10.1038/s41467-024-55738-1
slowing and reversing liver fibrosis, which can significantly
improve both the symptoms and biochemical markers of the 2. Tao J, Wu Z, Liang Y, et al. Lhx2 specifically expressed in
disease. Notably, gene therapy has emerged as a promising HSCs promotes liver regeneration and inhibits liver fibrosis.
133
Hepatology. 2024.
approach, with several therapies relying on viral vectors
to deliver nucleic acid cargo into target cells. Interestingly, doi: 10.1097/HEP.0000000000001201
modern molecular biology technology and equipment 3. Kim HY, Rosenthal SB, Liu X, et al. Multi-modal analysis
have facilitated the identification of distinctive and effective of human hepatic stellate cells identifies novel therapeutic
bioactive ingredients and formulations from the complex targets for metabolic dysfunction-associated steatotic liver
TCM. Hence, accurate exploration of TCM through disease. J Hepatol. 2024.
pharmacological network analysis may provide a promising doi: 10.1016/j.jhep.2024.10.044
solution for overcoming challenges in anti-fibrotic drug 4. Tung HC, Kim JW, Zhu J, et al. Inhibition of heme-thiolate
development. More effective combination strategies of monooxygenase CYP1B1 prevents hepatic stellate cell
modern and traditional treatments can be adopted for the activation and liver fibrosis by accumulating trehalose. Sci
pathological features of different stages of liver fibrosis. Transl Med. 2024;16(766):eadk8446.

Acknowledgments doi: 10.1126/scitranslmed.adk8446
5. Deng Y, Lu L, Zhu D, et al. MafG/MYH9-LCN2 axis promotes
None.
liver fibrosis through inhibiting ferroptosis of hepatic stellate
Funding cells. Cell Death Differ. 2024;31(9):1127-1139.
doi: 10.1038/s41418-024-01322-5
This study is supported by the National Natural Science
Foundation of China (32200936, 82200070, 82304589), the 6. Babuta M, Morel C, de Carvalho Ribeiro M, et al.
Guangdong Basic and Applied Basic Research Foundation Neutrophil extracellular traps activate hepatic stellate cells
and monocytes via NLRP3 sensing in alcohol-induced
(2021A1515110561, 2021A1515111049), the Guangdong acceleration of MASH fibrosis. Gut. 2024;73(11):1854-1869.
Provincial Key Laboratory of Tumor Interventional
Diagnosis and Treatment (2021B1212040004), and the doi: 10.1136/gutjnl-2023-331447
Xiangshan Talent Scientific Research Start-up Fund of 7. Tian Y, Ni Y, Zhang T, Cao Y, Zhou M, Zhao C. Targeting
Zhuhai People’s Hospital (2021XSYC-07). hepatic macrophages for non-alcoholic fatty liver disease
therapy. Front Cell Dev Biol. 2024;12:1444198.
Conflict of interest doi: 10.3389/fcell.2024.1444198

The authors declare they have no competing interests. 8. Bradic I, Kuentzel KB, Pirchheim A, et al. From LAL-D to
MASLD: Insights into the role of LAL and Kupffer cells in
Author contributions liver inflammation and lipid metabolism. Biochim Biophys
Conceptualization: Jian Sun, Xiaoguang Zhao Acta Mol Cell Biol Lipids. 2025;1870(1):159575.
Writing–original draft: Xin Liu, Chongmiao Yang, Yanyan doi: 10.1016/j.bbalip.2024.159575
Liu, Xiaowen Lin, Wei Su 9. Lee J, Woo H, Kang H, Park YK, Lee JY. Nicotinamide
Writing–review & editing: Jian Sun, Xiaoguang Zhao riboside targets mitochondrial unfolded protein response
to reduce alcohol-induced damage in Kupffer cells. J Pathol.
Ethics approval and consent to participate 2025;265(1):110-122.
Not applicable. doi: 10.1002/path.6372

Consent for publication 10. Fima R, Dussaud S, Benbida C, et al. Loss of embryonically-
derived Kupffer cells during hypercholesterolemia
Not applicable. accelerates atherosclerosis development. Nat Commun.

Volume 9 Issue 3 (2025) 12 doi: 10.36922/ejmo.8125